Neoplasms

Blood and Lymph Conditions

Immune System Diseases

All Conditions

Symptoms and General Pathology

Rare Diseases

Lymphoma

Leukemia

Precursor Cell Lymphoblastic Leukemia-Lymphoma

Leukemia, Lymphoid

Leukemia, Lymphocytic, Chronic, B-Cell

Lymphoma, B-Cell

Neoplasms by Histologic Type

Lymphoproliferative Disorders

Lymphatic Diseases

Immunoproliferative Disorders

Hematologic Diseases

Leukemia, B-Cell

Chronic Disease

Disease Attributes

Lymphoma, Non-Hodgkin

Lymphosarcoma

Acute Lymphoblastic Leukemia

Lymphoblastic Lymphoma

Chronic Graft Versus Host Disease

Chronic Lymphocytic Leukemia

B-cell Lymphoma

Acute Graft Versus Host Disease

Antineoplastic Agents

Antirheumatic Agents

All Drugs and Chemicals

Analgesics

Cyclophosphamide

Fludarabine

Fludarabine phosphate

Bendamustine Hydrochloride

Interleukin-2

Immunosuppressive Agents

Immunologic Factors

Antineoplastic Agents, Alkylating

Alkylating Agents

Analgesics, Non-Narcotic

FT819 single-dose monotherapy in adult subjects with r/r B-cell Lymphoma

FT819 single-dose in combination with IL-2 in adult subjects with r/r B-cell Lymphoma

FT819 monotherapy administered as step-fractionated dosing in adult subjects with r/r B-cell Lymphoma

FT819 single-dose monotherapy in adult subjects with r/r CLL

FT819 single-dose in combination with IL-2 in adult subjects with r/r CLL

FT819 monotherapy administered as step-fractionated dosing in adult subjects with r/r CLL

FT819 single-dose monotherapy in adult subjects with r/r B-ALL

FT819 single-dose in combination with IL-2 in adult subjects with r/r B-ALL

FT819 monotherapy administered as step-fractionated dosing in adult subjects with r/r B-ALL

FT819 monotherapy administered as step-fractionated dosing in combination with IL-2 in adult subjects with r/r B-cell Lymphoma

FT819 monotherapy administered as step-fractionated dosing in combination with IL-2 in adult subjects with r/r CLL

FT819 monotherapy administered as step-fractionated dosing in combination with IL-2 in adult subjects with r/r B-ALL

FT819

IL-2

Bendamustine

Fate Trial Disclosure

Januario Castro

Joseph Tuscano, MD

Madiha Iqbal, MBBS, MD

Saad Kendarian

This is a Phase I dose-finding study of FT819 as monotherapy and in combination with IL-2 in subjects with relapsed/refractory B-cell Lymphoma, Chronic Lymphocytic Leukemia and Precursor B-cell Acute Lymphoblastic Leukemia. The study will consist of a dose-escalation stage and an expansion stage where participants will be enrolled into indication-specific cohorts.

FT819 in Subjects With B-cell Malignancies

A Phase I Study of FT819 in Subjects With B-cell Malignancies

The PK of FT819 in peripheral blood will be reported as the relative percentage of product (FT819) DNA versus patient DNA (% chimerism) measured from blood samples at the specified time points

Fate Therapeutics

Respiratory Tract (Lung and Bronchial) Diseases

Lung Neoplasms

Carcinoma, Non-Small-Cell Lung

Carcinoma

Respiratory Tract Neoplasms

Thoracic Neoplasms

Lung Diseases

Respiratory Tract Diseases

Carcinoma, Bronchogenic

Bronchial Neoplasms

Reproductive Control Agents

Docetaxel

Gossypol acetic acid

Gossypol

Tubulin Modulators

Antimitotic Agents

AT-101 30 mg bid on days 1, 2, and 3 of each 21 day cycle, docetaxel, 75 mg/m2 on day 1 of each 21 day cycle; until progression or unacceptable toxicity develops

AT-101 and docetaxel

placebo 3 tabs bid on days 1, 2, and 3 of each 21 day cycle, docetaxel, 75 mg/m2 on day 1 of each 21 day cycle; until progression or unacceptable toxicity develops

placebo and docetaxel

Lance Leopold, MD

This is a double- blind, multicenter, randomized Phase II study to evaluate the efficacy and safety of AT-101 in combination with docetaxel in relapsed/refractory non-small cell lung cancer

Further Study Details provided by Ascenta.

A Randomized Phase 2 Study of AT-101 in Combination With Docetaxel in Relapsed/Refractory Non-Small Cell Lung Cancer

A Phase 2, Randomized, 2-Arm, Double-Blind Study of AT-101 in Combination With Docetaxel Versus Docetaxel Plus Placebo in Patients With Relapsed or Refractory Non-Small Cell Lung Cancer (NSCLC)

Ascenta Therapeutics

Brian Wood, Associate Director, Clinical Development

Cicatrix

Universal CD19-specific CAR gene-engineered T cells

Lung-Ji Chang, Ph.D

The purpose of this study is to assess the feasibility, safety and efficacy of universal CAR T cell therapy against CD19-positive hematological malignancies using a novel CD19-specific CAR T cell product, 4SCAR19U T cells. The study also aims to learn more about the function of the 4SCAR19U T cells and their persistence in patients. This is a phase I trial enrolling patients from multiple clinical centers.

Chimeric antigen receptor (CAR) T cell therapy has proven effective in treating B cell malignancies. However, the application itself is still limited by the high cost and long preparation time which often do not meet the urgent need of patients. In addition, some patients may suffer from long-term immunosuppression caused by tumor microenvironment or after radiotherapy and chemotherapy, resulting in exhaustion, aging and functional defects of the autologous T cells, which will eventually affect the quality of the CAR-T cells and affect the clinical efficacy.

The 4SCAR19U T cells are genetically engineered and manufactured in bulk amount that can be supplied off-the-shelf without being custom made from individual patients. The immediate availability of the CAR-T cells makes clinical treatment convenient and timely for rapid progressing disease or for the highly immune suppressed patients. This application can be time- and cost-effective. This novel approach may also overcome problems of functionally defective autologous T cells. The purpose of this clinical trial is to assess the feasibility, safety and efficacy of the 4SCAR19U T cell product in hematological malignancies. Another goal of the study is to learn more about the function of this novel product and its persistence in the patients

4SCAR19U T Cells Targeting B Cell Malignancies

Universal 4SCAR19U T Cell Therapy for the Treatment of Relapsed and Refractory B Cell Malignancies

Safety of 4SCAR19U T cells in patients with relapsed and refractory B-ALL, BCL using CTCAE 4 standard to evaluate the level of adverse events

Objective responses (complete response (CR) + partial response (PR)) are assessed by the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 criteria.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
FT819 in Subjects With B-cell Malignancies	NCT04629729	Lymphoma, B-Cel... Chronic Lymphoc... Precursor B-Cel...	FT819 Cyclophosphamid... Fludarabine IL-2 Bendamustine	18 Years -	Fate Therapeutics
A Randomized Phase 2 Study of AT-101 in Combination With Docetaxel in Relapsed/Refractory Non-Small Cell Lung Cancer	NCT00544960	Non-small Cell ...	AT-101 and doce... placebo and doc...	18 Years -	Ascenta Therapeutics
4SCAR19U T Cells Targeting B Cell Malignancies	NCT05995015	B Cell Malignan...	Universal CD19-...	6 Months - 75 Years	Shenzhen Geno-Immune Medical Institute
FT819 in Subjects With B-cell Malignancies	NCT04629729	Lymphoma, B-Cel... Chronic Lymphoc... Precursor B-Cel...	FT819 Cyclophosphamid... Fludarabine IL-2 Bendamustine	18 Years -	Fate Therapeutics

Spots Global Cancer Trial Database for bcl

Every month we try and update this database with for bcl cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Spots Global Cancer Trial Database for bcl

Every month we try and update this database with for bcl cancer trials from around the world to help patients and their families find trials that might be right for them. We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Every month we try and update this database with for bcl cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.